Akums Drugs & Pharmaceuticals Ltd

- No explicit mention of any current or planned new fundraising through debt or equity in the transcript. - IPO proceeds have already been received and largely utilized till November 2024. - The company has a positive net cash flow of Rs. 341 crore and positive cash flow from operations (Rs. 71 crore for H1 September 2024). - Long-term credit rating improved to AA Stable by ICRA, indicating good financial health and borrowing capacity. - Management discusses ongoing investments in CAPEX and R&D funded from existing resources. - No stated plans for fresh debt or equity fundraising in the near term were disclosed during the call.

- Land acquisition for Jammu plants completed; civil works to begin shortly with commercial production expected in FY26-27. - Continued investment in API R&D with over 80 scientists; Rs. 7 crore spent in H1 FY25 and a total of Rs. 30 crore till date. - Significant CAPEX of around Rs. 150 crore spent in H1 FY25 to build production capability. - New injectable facility in Haridwar started commercial production in Q2 with ampoule and SVP FFS lines operational; vial and lyophilized vial production to begin in Q3; LVP FFS line to be operational by Q4. - Expansion of glass ampoules, FFS ampoules, and lyophilization capacity underway to meet growing demand. - MoU signed with Government of Zambia for a joint venture to set up pharmaceutical manufacturing facility, expected to take 18-24 months to set up. - Filed 2 dossiers in Europe; building pipeline for European and other export markets.

- The company expects overall growth toward a better future with positive volume trends continuing (Page 13). - CDMO business saw an 11% volume decline in Q2 but is expected to stabilize and grow in H2 and FY26 (Pages 10-11). - API prices, which have impacted revenues, are expected to normalize by Q3 or Q4 FY25, potentially boosting financials (Page 9). - Export markets including Europe and Africa are key growth drivers, with dossiers filed and manufacturing setups underway; commercial benefits expected in a couple of fiscals, quicker ramp-up in Zambia (~18-24 months) (Pages 5, 7, 8). - Trade generic business is being scaled down but expected to reach positive monthly EBITDA by H2 FY25 (Page 11). - Continuous R&D investment aims to add new products and therapies to the pipeline to drive future growth (Page 13). - Market share in CDMO business is currently stable and expected to increase with new plant capacities coming online (Pages 9-11).

- Company expects growth driven by new product pipelines, R&D (400 scientists), and process improvements. - Anticipates volume growth in CDMO business to stabilize and grow by FY26; no loss of market share expected. - API business impacted by falling prices; EBITDA breakeven now expected 6 months after Q2 FY25, possibly delayed beyond Q4 FY25. - Export business (Europe, Africa, Zambia JV) expected to yield commercial benefits in next 2-3 years. - Margins impacted short-term by softer API prices, but stability is expected in H2 FY25 with potential normalization in Q3/Q4. - Trade generic segment being scaled down; expected to break even monthly by H2 FY25. - Long-term outlook positive with investments in injectables, new facilities, and new therapies such as patented sickle cell product and others. - Stakeholders including investors expected to benefit as company scales operations and market position globally.

- Akums Drugs and Pharmaceuticals Limited has a robust pipeline with over 350 dossiers pending in South-East Asia, African, Middle East, and European markets. - The company received more than 80 approvals in the first half of the fiscal year, indicating steady progress in order fulfillment. - They are expanding their product portfolio from oral solid dosage (OSD) to injectables, with new plants being commissioned in Europe and India. - Strong focus on filing dossiers in export markets, expecting commercial benefits mostly within the next 2 fiscal years, especially from Europe and Zambia. - The injectable facility at Haridwar is being commissioned in phases, adding to future manufacturing capacity. - Approximately 26 out of the top 30 Pharma companies in India are long-standing clients, indicating strong demand and ongoing orders. - Growth initiatives in new therapies and government-linked projects also imply a growing orderbook for the future.